INTRODUCTION: Laparoscopic adrenalectomy (LA) is a safe minimally invasive approach for treatment of pheochromocytoma (PHEO). Posterior retroperitoneoscopic adrenalectomy (PRA) is an alternative minimally invasive technique; however, there is a lack of data regarding the appropriateness of this approach in patients with PHEO. METHODS: Our endocrine surgery database was queried to identify patients who underwent LA or PRA for PHEO. Patient and tumor characteristics, as well as operative details and postoperative course were compared between the 2 groups. RESULTS: LA or PRA was attempted in 46 patients with PHEO (23 LA, 23 PRA). There were no differences in age, BMI, or tumor size between these groups. PRA was associated with significantly reduced operative times (99 min vs 145 min, P < .001), estimated blood loss (8.4 cc vs 123.8 cc, P = .02), and postoperative length of stay (1.9 nights vs 3.1 nights, P < .01). There was no significant difference in rates of conversion to an open procedure or perioperative complications between these groups. CONCLUSION: LA and PRA are both safe and effective approaches in patients with PHEO. In our experience, PRA results in decreased operative times, blood loss, and postoperative length of stay compared with LA. PRA has become our preferred approach for patients with PHEO.
INTRODUCTION: Laparoscopic adrenalectomy (LA) is a safe minimally invasive approach for treatment of pheochromocytoma (PHEO). Posterior retroperitoneoscopic adrenalectomy (PRA) is an alternative minimally invasive technique; however, there is a lack of data regarding the appropriateness of this approach in patients with PHEO. METHODS: Our endocrine surgery database was queried to identify patients who underwent LA or PRA for PHEO. Patient and tumor characteristics, as well as operative details and postoperative course were compared between the 2 groups. RESULTS: LA or PRA was attempted in 46 patients with PHEO (23 LA, 23 PRA). There were no differences in age, BMI, or tumor size between these groups. PRA was associated with significantly reduced operative times (99 min vs 145 min, P < .001), estimated blood loss (8.4 cc vs 123.8 cc, P = .02), and postoperative length of stay (1.9 nights vs 3.1 nights, P < .01). There was no significant difference in rates of conversion to an open procedure or perioperative complications between these groups. CONCLUSION: LA and PRA are both safe and effective approaches in patients with PHEO. In our experience, PRA results in decreased operative times, blood loss, and postoperative length of stay compared with LA. PRA has become our preferred approach for patients with PHEO.
Authors: Alessandro M Paganini; Mario Guerrieri; Andrea Balla; Silvia Quaresima; Andrea M Isidori; Franco Iafrate; Giancarlo D'Ambrosio; Giovanni Lezoche; Emanuele Lezoche Journal: Langenbecks Arch Surg Date: 2015-12-18 Impact factor: 3.445
Authors: Laurent Brunaud; Phi-Linh Nguyen-Thi; Eric Mirallie; Marco Raffaelli; Menno Vriens; Pierre-Etienne Theveniaud; Myriam Boutami; Brendan M Finnerty; Wessel M C M Vorselaars; Inne Borel Rinkes; Rocco Bellantone; Celestino Lombardi; Thomas Fahey; Rasa Zarnegar; Laurent Bresler Journal: Surg Endosc Date: 2015-06-20 Impact factor: 4.584
Authors: Alessandro M Paganini; Andrea Balla; Mario Guerrieri; Giovanni Lezoche; Roberto Campagnacci; Giancarlo D'Ambrosio; Silvia Quaresima; Maria Vittoria Antonica; Emanuele Lezoche Journal: Surg Endosc Date: 2014-04-16 Impact factor: 4.584
Authors: M Thomaschewski; H Neeff; T Keck; H P H Neumann; T Strate; E von Dobschuetz Journal: Rev Endocr Metab Disord Date: 2017-12 Impact factor: 6.514